Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

125

Participants

Timeline

Start Date

April 18, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

October 31, 2029

Conditions

Locally Advanced or Metastatic Solid Tumors

Interventions

DRUG

DA-4505

Phase 1a: Dose escalation Phase 1b: OBD and MTD Phase 2a: RP2D

DRUG

DA-4505 + Pembrolizumab

Phase 1a/b: OBD, MTD of DA-4505 + 200mg of Pembrolizumab Phase 2a: RP2D of DA-4505 + 200mg of Pembrolizumab

Trial Locations (2)

RECRUITING

Asan Medical Center, Seoul

RECRUITING

Severance Hospital, Seoul

All Listed Sponsors

lead

Dong-A ST Co., Ltd.

INDUSTRY